Dr. Febbo’s [Damon Runyon-Lilly Clinical Investigator] research focuses on applying genomic technologies to better understanding the biology and clinical behavior of prostate cancer.  His work has demonstrated that the expression of 5 genes can be used to predict the recurrence of prostate cancer following surgery.  This finding indicates that DNA microarrays (or DNA chips) can sensitively and broadly detect variation in genetic expression and thereby monitor cellular biology.   Dr. Febbo is currently testing the model in the setting of a national, prospective trial through a cooperative cancer group and working to adapt this and similar models for clinical application.

Recent Discoveries:

• May 26, 2009 > Low-carbohydrate diet may slow prostate tumor growth
• March 16, 2009 > Gene expression signature discovered for metastatic prostate cancer

 

---

Project Title: "Mechanisms of docetaxel resistance in metastatic prostate cancer"

Institution: Duke University

Sponsor(s) / Mentor(s): Joseph Nevins, PhD, and Herbert Kim Lyerly, MD

Cancer Type: Prostate

Research Area: Genomics